Levosert

Levonorgestrel, the active ingredient in Levosert, is a Progestin (levonorgestrel) intrauterine system presented as a 52 mg intrauterine system for intrauterine use. It provides long‑acting reversible contraception and can be used to treat heavy menstrual bleeding.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosert, a levonorgestrel‑releasing intrauterine system, is indicated for hormonal contraceptive and menstrual‑bleeding management pathways.

- Contraception: provides highly effective, long‑acting reversible birth control for up to five years. - Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with excessive bleeding. - Endometrial suppression: helps prevent endometrial overgrowth during prolonged use.

Levosert may cause a range of adverse reactions. Most are mild and resolve with continued use.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal cramping - Hormonal acne - Breast tenderness - Headache

Serious or Rare Side Effects: - Uterine perforation during insertion - Expulsion of the device - Pelvic inflammatory disease or infection - Ectopic pregnancy if contraception fails - Allergic reaction to levonorgestrel or device materials - Migration of the IUS to adjacent organs

Before insertion and during use, certain precautions should be observed.

- Pregnancy testing: confirm non‑pregnant status prior to insertion. - Uterine evaluation: assess for fibroids, septum, or other anomalies that may impede placement. - Infection risk: treat any active pelvic infection before device insertion. - Breast cancer history: avoid use in current or past estrogen‑dependent breast cancer. - Medication review: assess concomitant drugs that could alter bleeding patterns. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levosert may interact with systemic medications that affect levonorgestrel metabolism or bleeding patterns.

Major Interactions (Avoid): - Rifampicin and other strong CYP3A4 inducers: may reduce contraceptive efficacy. - Antiepileptic enzyme inducers (carbamazepine, phenytoin, phenobarbital): may lower levonorgestrel levels.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly affect bleeding patterns. - Antifungal azoles (ketoconazole): may increase levonorgestrel exposure. - Concurrent estrogen‑containing hormonal therapies: may increase overall hormonal load and affect side‑effect profile.